NSGO-CTU Biannual Investigator Meeting
28-29 November 2019

Radisson Blu Scandinavia Hotel, Copenhagen
Amager Blvd. 70, 2300 København

This meeting is partly sponsored by

AstraZeneca
Clovis Oncology
Roche
TESARO
Thursday 28 November 2019
19.00 – 21.20 NSGO-CTU Symposium
Chair: Johanna Mäenpää, Tampere, Finland

PARP inhibitors in combination
19.00 – 19.20 Rationale and clinical evidence of PARP inhibitors in combination with other novel agents, Mansoor Raza Mirza, NSGO-CTU
19.20 – 20.00 PAOLA study results and beyond, Eric Pujade-Lauraine, GINECO, France
20.00 – 20.20 Translation research in PARP inhibitor, Line Bjørge, Bergen, Norway
20.20 – 21.20 Panel discussion
   Eric Pujade-Lauraine, GINECO, France
   Johanna Mäenpää, Tampere, Finland
   Susanne Malander, Lund, Sweden
   Line Bjørge, Bergen, Norway
   Henrik Roed, Copenhagen, Denmark
   Ingvild Vistad, Kristiansand, Norway
   Mansoor Raza Mirza, NSGO-CTU

NSGO-CTU Scientific Symposium is an official part of NSGO-CTU Biannual Investigator meeting program with NSGO-CTU being solely responsible for the content. The Symposium is supported by a sponsorship from a pharmaceutical company.

Friday 29 November 2019
07.30 – 08.00 Registration/coffee
08.00 – 09.40 NSGO-CTU Symposium
Chair: Kristina Lindemann, Oslo, Norway

Patient’s perspective
08:00 – 08:40 Patient’s acceptance of novel treatments, Jalid Sehouli, Berlin, Germany
08:40 – 08:55 Patient’s view, Birthe Lemley, KIU, Denmark
08:55 – 09:10 "No decision about me – without me" – Shared decision making as a concept, Karina Dahl Steffensen, Vejle, Denmark
09:10 – 09:25 The role of patient-reported outcomes in palliation, Kristina Lindemann, Oslo, Norway
09:25 – 09.45 Panel Discussion
   Jalid Sehouli, Berlin, Germany
   Maria Dimoula, Sahlgrenska, Sweden
   Karina Dahl Steffensen, Vejle, Denmark
   Annika Auranen, Tampere, Finland
   Gitte-Bettina Nyvang, Odense, Denmark

NSGO-CTU Scientific Symposium is an official part of NSGO-CTU Biannual Investigator meeting program with NSGO-CTU being solely responsible for the content. The Symposium is supported by a sponsorship from a pharmaceutical company.
10.00 – 10.05 Welcome  
Mansoor Raza Mirza, NSGO-CTU

10.05 – 10.15 Future plans and status report of NSGO-CTU activities, Mansoor Raza Mirza, NSGO-CTU

OVARIAN CANCER
10.15 – 10.45 Surgical trials – Scientific rational, evidence for and study designs will be presented followed by a panel discussion to discuss potential impact.  
Chair: Johanna Mäenpää, Tampere, Finland

10.15 – 10.25 Overview of Surgical trials:  
- AGO-OVAR OP.4/DESKTOP III  
- TRUST  
Johanna Mäenpää, Tampere, Finland

10.25 – 10.35 OVHIPEC-2  
Berit Jul Mosgaard, Copenhagen, Denmark

10.35 – 10.45 Panel discussion  
Ulla Puistola, Oulu, Finland  
Päivi Lindvall Kannisto, Lund, Sweden  
Yun Wang, Oslo, Norway  
Berit Jul Mosgaard, Copenhagen, Denmark

OVARIAN CANCER
10.45 – 11.45 First line trials - Scientific rational, evidence for and study designs will be presented followed by a panel discussion to discuss potential impact of outcome  
Chair: Henrik Roed, Copenhagen, Denmark

10.45 – 11.00 Overview of First line trials:  
- AGO-OVAR 17/BOOST  
- AGO-OVAR12  
- AGO-OVAR16  
- ENGOT-ov39/IMagyn050  
- ENGOT-ov25/PAOLA-1  
- PRIMA/ENGOT-OV26/GOG-3012  
Henrik Roed, Copenhagen, Denmark

11.00 – 11.10 ENGOT-ov44/First - An adaptive Randomized Phase 3 Comparison of Standard Platinum Based Treatment Versus Platinum and TSR-042 followed by Niraparib and TSR-042 maintenance Therapy in Patients with epithelial Stage III or IV Cancer of the Ovary, Fallopian Tube, or Peritoneum  
Gitte-Bettina Nyvang, Odense, Denmark
11.10 – 11.20 **DUO-O** - Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of durvalumab in combination with chemotherapy and bevacizumab followed by maintenance durvalumab, bevacizumab and olaparib in newly diagnosed advanced ovarian cancer patients

*Maarit Anttila, Kuopio, Finland*

11.20 – 11.30 **ENGOT-ov45/NCRI/ATHENA** - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment following Response to Front-Line Platinum-Based Chemotherapy

*Susanne Malander, Lund, Sweden*

11.30 – 11.45 **Panel discussion**

*Gitte-Bettina Nyvang, Odense, Denmark*

*Maarit Anttila, Kuopio, Finland*

*Susanne Malander, Lund, Sweden*

*Henna Kärkkäinen, Kuopio, Finland*

*Kristine Madsen, Copenhagen, Denmark*

*Nicolene Raaschou-Jensen, Herlev, Denmark*

*Birute Brasiuniene, Vilnius, Lithuania*

**OVARIAN CANCER**

11.45 – 12.40 **Relapsed disease** - Scientific rational, evidence for and study designs will be presented followed by a panel discussion to discuss potential impact of outcome

*Chair: Line Bjørge, Bergen, Norway*

11.45 – 11.55 **Overview of trials where platinum is an option:**

- **INOVATYON**
- **ENGOT-ov16/NOVA**
- **ENGOT-ov24-NSGO/AVANOVA**
- **ENGOT-ov38/OReO**

*Line Bjørge, Bergen, Norway*

11.55 – 12.05 **ENGOT-OV42-NSGO/AVATAR** – A three-arm randomized study to evaluate the efficacy of niraparib-bevacizumab-dostarlimab triplet combination against niraparib-bevacizumab doublet combination and against standard of care therapy in Women with relapsed ovarian cancer where platinum combination therapy is an option.

*Mansoor Mirza, NSGO-CTU*
12.05 – 12.20 Panel discussion
  Synnöve Staff, Tampere, Finland
  Hanna Dahlstrand, Uppsala, Sweden
  Morten Jørgensen, Rigshospitalet, Denmark
  Elisabeth Berge Nilsen, Stavanger, Norway
  Mansoor Raza Mirza, NSGO-CTU

LUNCH 12.20-13.20

OVARIAN CANCER
13.20 – 13.40 Relapsed disease - Scientific rational, evidence for and study designs will be presented followed by a panel discussion to discuss potential impact of outcome 
Chair: Annika Auranen, Tampere, Finland

13.20 – 13.30 ENGOT-ov34/2.29 – Atezolizumab in combination with Bevacizumab and Chemotherapy versus Chemo-Bevacizumab standard in recurrent ovarian cancer – a randomized Phase III trial 
  Sakari Hietanen, Turku, Finland

13.30 – 13.40 ENGOT-ov30/NSGO-UMBRELLA – A multicenter, phase 2, open-label non-randomized study to obtain preliminary evidence of efficacy of several novel combinations in relapsed ovarian cancer. This information regards Cohorte A, MEDI9447 and Durvalumab 
  Liv Cecilie Vestrheim Thomsen, Bergen, Norway

13.40 – 13.50 Panel discussion 
  Sakari Hietanen, Turku, Finland
  Mansoor Raza Mirza, NSGO-CTU
  Liv Cecilie Vestrheim Thomsen, Bergen, Norway
  Ulla Puistola, Oulu, Finland
  Elisabeth Berge Nilsen, Stavanger, Norway
  Gerli Kuusk, Tallinn, Estonia

ENDOMETRIAL CANCER
13.50 – 14.45 Endometrial Cancer - Scientific rational, evidence for and study designs will be presented followed by a panel discussion to discuss potential impact of outcome 
Chair: Caroline Lundgren, Karolinska, Sweden

13.50 – 14.00 ENGOT-EN2-DGCC – A phase III Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer 
  Bente Lunde, Aalborg, Denmark
14.00 – 14.10 **ENGOT-EN1/FANDANGO** – A Randomized Phase II Trial of First-line Combination Chemotherapy with Nintedanib / Placebo for Patients With Advanced or Recurrent Endometrial Cancer
*Hanna Dahlstrand, Uppsala, Sweden*

14.10 – 14.20 **ENGOT-EN3-NSGO/PALEO** – A randomized, double-blind, placebo-controlled, phase II trial of Palbociclib in combination with Letrozole versus Placebo in combination with Letrozole for patients with Estrogen Receptor Positive advanced or recurrent Endometrial cancer
*Anne Dørum, Oslo, Norway*

*Mansoor Raza Mirza, NSGO-CTU*

14.30 – 14.45 **Panel discussion**
*Bente Lund, Aalborg, Denmark*
*Hanna Dahlstrand, Uppsala, Sweden*
*Anne Dørum, Oslo, Norway*
*Mansoor Raza Mirza, NSGO-CTU*
*Marjut Rintala, Turku, Finland*
*Kathrine Woie, Bergen, Norway*
*Karin Grisan, Tartu, Estonia*

**COFFEE** 14.45 – 15.05

**CERVICAL and VULVAR CANCER**

15.05 – 16.30 **Cervical Cancer** - Scientific rational, evidence for and study designs will be presented followed by a panel discussion to discuss potential impact of outcome
*Chair: Ane Gerda Zahl Eriksson, Oslo, Norway*

15.05 – 15.15 Update of minimal invasive surgery – **RACC trial**
*Sahar Salehi, Stockholm, Sweden*

15.15 – 15.25 **ENGOT-cx7-NSGO/MaRuC**
*ENGOT-cx11* – A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer
*Mansoor Raza Mirza, NSGO-CTU*

15.25 – 15.35 **ENGOT-cx10/GEICO 68-C/BEAT cc** – A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent or Recurrent Carcinoma of the Cervix
*Kristina Lindemann, Oslo, Norway*
15.35 – 15.45 **ENGOT-cx13/AGO/FERMATA** – An International Randomized Double-blind Clinical Trial of BCD-100 Plus Platinum-based Chemotherapy with and without Bevacizumab versus Placebo Plus Platinum-based Chemotherapy with and without Bevacizumab as First-Line Treatment of Subjects with Advanced Cervical Cancer

*Farrukh Chaudhary, Herlev, Denmark*

15.45 – 15.55 **ENGOT-cx6** – Tisotumab Vedotin in Previously treated recurrent or metastatic cervical cancer.

**ENGOT-cx8** – Randomized, open label, phase 1b/2 first line trial with Tisotumab Vedotin.

**ENGOT-cx12** – A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer.

*Lars Fokdal, Århus, Denmark*

15.55 – 16.05 **GROINSS V III**

*Kristina Lindemann, Oslo, Norway*

16.05 – 16.15 **PEACE** – Palliation in gynae-oncology: Evaluation and Assessment of satisfaction with care

*Kristina Lindemann, Oslo, Norway*

16.15 – 16.30 **Panel discussion**

*Sahar Salehi, Stockholm, Sweden*

*Mansoor Raza Mirza, NSGO-CTU*

*Kristina Lindemann, Oslo, Norway*

*Farrukh Chaudhary, Herlev, Denmark*

*Lars Fokdal, Århus, Denmark*

*Johanna Mäenpää, Tampere, Finland*

*Birutė Brasiauniene, Vilnius, Lithuania*

16.30 – 16.40 **End of meeting**

*Mansoor Raza Mirza, NSGO-CTU*

NSGO-CTU will reimburse travel expenses maximum 200 Euros each for one investigator and one research nurse from an NSGO site.